Research Papers:

Optimization of EGFR mutation detection by the fully-automated qPCR-based Idylla system on tumor tissue from patients with non-small cell lung cancer

Marius Ilie, Catherine Butori, Sandra Lassalle, Simon Heeke, Nicolas Piton, Jean-Christophe Sabourin, Virginie Tanga, Kevin Washetine, Elodie Long-Mira, Priscilla Maitre, Nathalie Yazbeck, Olivier Bordone, Virginie Lespinet, Sylvie Leroy, Charlotte Cohen, Jérôme Mouroux, Charles Hugo Marquette, Véronique Hofman and Paul Hofman _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:103055-103062. https://doi.org/10.18632/oncotarget.21476

Metrics: PDF 2236 views  |   HTML 2656 views  |   ?  


Marius Ilie1,2,3, Catherine Butori1,3, Sandra Lassalle1,2,3, Simon Heeke2, Nicolas Piton4, Jean-Christophe Sabourin4, Virginie Tanga3, Kevin Washetine1,3, Elodie Long-Mira1,2,3, Priscilla Maitre3, Nathalie Yazbeck2, Olivier Bordone3, Virginie Lespinet3, Sylvie Leroy5, Charlotte Cohen6, Jérôme Mouroux2,6, Charles Hugo Marquette2,5, Véronique Hofman1,2,3 and Paul Hofman1,2,3

1Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, FHU OncoAge, University Côte d’Azur, Nice, France

2IRCAN Inserm U1081/CNRS 7284, FHU OncoAge, University Côte d’Azur, Nice, France

3Hospital-related Biobank (BB-0033-00025), Pasteur Hospital, FHU OncoAge, University Côte d’Azur, Nice, France

4Department of Pathology, Rouen University Hospital, Rouen, France

5Department of Pulmonary Medicine and Thoracic Oncology, Pasteur Hospital, FHU OncoAge, University Côte d’Azur, Nice, France

6Department of Thoracic Surgery, Pasteur Hospital, FHU OncoAge, University Côte d’Azur, Nice, France

Correspondence to:

Paul Hofman, email: [email protected]

Keywords: NSCLC, EGFR, targeted therapy, optimization, PCR

Received: March 21, 2017     Accepted: September 19, 2017     Published: October 04, 2017


Treatment with EGFR inhibitors is limited to patients with advanced/metastatic non-small cell lung cancer who have known EGFR mutations. Currently, patient care has to respond to several imperatives to make these inhibitors broadly available to all patients; fast and accurate detection of EGFR mutations by a sensitive and specific standardized cost-effective method, easy-to-implement in settings with limited expertise in molecular diagnostics.

We evaluated the Idylla™ EGFR Mutation Assay (Biocartis) for the detection of EGFR mutations in archived formalin-fixed paraffin-embedded (FFPE) tumor samples from a series of 55 patients with lung adenocarcinoma and compared these results with those obtained by a pyrosequencing ISO-15189 accredited laboratory method. The comparison was made on both whole surgical tumor sections and on three artificially constructed small biopsies (~1 mm) from the same FFPE blocks. Cost-effectiveness and turnaround time comparison between the two methods was performed.

On both whole tissue sections and on biopsy cores, the Idylla™ and pyrosequencing had an agreement of 95% (52/55). The Idylla™ EGFR Assay produced results faster and more cost-effective than pyrosequencing.

The Idylla™ system showed a good sensitivity and was cost-saving in our setting. Because of the easy workflow, the Idylla™ system has the potential to expand EGFR testing to more pathology laboratories in a reliable and fast manner.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21476